Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moshe Mittelman

Showing results (61-70 of 114) with videos related to

Pageof 12
Sort By:
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|January 30, 2015
Erythropoietin directly stimulates osteoclast precursors and induces bone lossSahar Hiram-Bab, Tamar Liron, Naamit Deshet-Unger, et al.
Journal of Pediatric Orthopedics|April 16, 2005
Disseminated thrombosis-induced growth plate necrosis in rat: a unique model for growth plate arrestMeir Nyska, Shay Shabat, Philip H Long, et al.
Blood|October 12, 2018
Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopeniaMichael Dickinson, Honar Cherif, Pierre Fenaux, et al.
Experimental and Toxicologic Pathology : Official Journal of the Gesellschaft Fur Toxikologische Pathologie|January 6, 2004
Ocular expression of vascular cell adhesion molecule (VCAM-1) in 2-butoxyethanol-induced hemolysis and thrombosis in female ratsAbraham Nyska, Cindy R Moomaw, Nathan Ezov, et al.
European Journal of Haematology|June 30, 2018
Can bone marrow cellularity help in predicting prognosis in myelodysplastic syndromes?Uri Greenbaum, Erel Joffe, Kalman Filanovsky, et al.
American Heart Journal|September 29, 2009
Blood transfusion for acute decompensated heart failure--friend or foe?Moshe Garty, Eytan Cohen, Alexander Zuchenko, et al.
Ejhaem|August 21, 2023
Next-generation sequencing of baseline genetic mutations and outcomes of eltrombopag and azacitidine therapy in patients with myelodysplastic syndromes and thrombocytopenia: Data from the SUPPORT clinical trialPedro Marques Ramos, Jeea Choi, Catarina D Campbell, et al.
Thrombosis Research|September 23, 2014
Erythropoiesis-stimulating agents and thrombotic events in dialysis patientsMarit M Suttorp, Tiny Hoekstra, Gürbey Ocak, et al.
Annals of Hematology|August 23, 2016
Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocolMoshe Mittelman, Kalman Filanovsky, Yishai Ofran, et al.
Therapeutic Advances in Hematology|August 11, 2021
Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective studyRoy Vitkon, Dan Netanely, Shai Levi, et al.
Pageof 12

Showing results (61-70 of 114) with videos related to

Sort By:
Pageof 12
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|January 30, 2015
Erythropoietin directly stimulates osteoclast precursors and induces bone lossSahar Hiram-Bab, Tamar Liron, Naamit Deshet-Unger, et al.
Journal of Pediatric Orthopedics|April 16, 2005
Disseminated thrombosis-induced growth plate necrosis in rat: a unique model for growth plate arrestMeir Nyska, Shay Shabat, Philip H Long, et al.
Blood|October 12, 2018
Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopeniaMichael Dickinson, Honar Cherif, Pierre Fenaux, et al.
Experimental and Toxicologic Pathology : Official Journal of the Gesellschaft Fur Toxikologische Pathologie|January 6, 2004
Ocular expression of vascular cell adhesion molecule (VCAM-1) in 2-butoxyethanol-induced hemolysis and thrombosis in female ratsAbraham Nyska, Cindy R Moomaw, Nathan Ezov, et al.
European Journal of Haematology|June 30, 2018
Can bone marrow cellularity help in predicting prognosis in myelodysplastic syndromes?Uri Greenbaum, Erel Joffe, Kalman Filanovsky, et al.
American Heart Journal|September 29, 2009
Blood transfusion for acute decompensated heart failure--friend or foe?Moshe Garty, Eytan Cohen, Alexander Zuchenko, et al.
Ejhaem|August 21, 2023
Next-generation sequencing of baseline genetic mutations and outcomes of eltrombopag and azacitidine therapy in patients with myelodysplastic syndromes and thrombocytopenia: Data from the SUPPORT clinical trialPedro Marques Ramos, Jeea Choi, Catarina D Campbell, et al.
Thrombosis Research|September 23, 2014
Erythropoiesis-stimulating agents and thrombotic events in dialysis patientsMarit M Suttorp, Tiny Hoekstra, Gürbey Ocak, et al.
Annals of Hematology|August 23, 2016
Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocolMoshe Mittelman, Kalman Filanovsky, Yishai Ofran, et al.
Therapeutic Advances in Hematology|August 11, 2021
Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective studyRoy Vitkon, Dan Netanely, Shai Levi, et al.
Pageof 12